AEGIRBIO AB SUCCESSFULLY COMPLETES AN ADDITIONAL MILESTONE OF RADx® TECH PROGRAM
Leading Diagnostics Innovator Advances Accessibility Project for Multiplex Testing
AegirBio AB, a forefront leader in saliva-based diagnostics solutions, proudly announces the successful completion of an additional Milestone in its participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program. AegirBio's phase 1 award, focusing on an accessibility project for multiplex testing, positions the company at the forefront of digital self-test platform development with potential milestone-based payments of up to USD 1.2 million.
The RADx® Tech program, comprising four milestones, is a strategic initiative by the NIH to accelerate the development and deployment of innovative diagnostic technologies. Today's announcement marks a significant stride forward for AegirBio in its mission to create a groundbreaking digital multiplex self-test platform that addresses the unique needs of individuals with disabilities.
In the specific accomplished Milestone, AegirBio's dedicated team has successfully developed magnetic-based tests for the simultaneous detection of three infectious viruses – SARS-CoV-2, Influenza A, and Influenza B – all from a single saliva sample. This technological breakthrough underscores AegirBio's commitment to advancing diagnostics accessibility and providing vital assistance to diverse user groups.
Statement by Marco Witteveen, CEO of AegirBio AB:
"This milestone achievement reinforces AegirBio's commitment to innovation and inclusivity. We are entering an exciting era where our vision of establishing a concrete foundation for growth and prosperity for all stakeholders is becoming a reality. Our team's dedication and the success of this Milestone underscore our culture of pushing boundaries and creating solutions that make a positive impact."
This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.
For additional information, please contact::
Marco Witteveen, CEO, Aegirbio AB
Email: ir@aegirbio.com
About Aegirbio
AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com
The company's Certified Adviser is Eminova Fondkomission AB; adviser@eminova.se